Related Experiment Video
Updated: Jan 19, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
Mahlet Z Tamirat1, Marika Koivu2,3,4, Klaus Elenius2,3,5
1Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.
Abstract:
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor important in diverse biological processes including cell proliferation and survival. Upregulation of EGFR activity due to over-expression or mutation is widely implicated in cancer. Activating somatic mutations of the EGFR kinase are postulated to affect the conformation and/or stability of the protein, shifting the EGFR inactive-active state equilibrium towards the activated state. Here, we examined a common EGFR deletion mutation, Δ746ELREA750, which is frequently observed in non-small cell lung cancer patients. By using molecular dynamics simulation, we investigated the structural effects of the mutation that lead to the experimentally reported increases in kinase activity. Simulations of the active form wild-type and ΔELREA EGFRs revealed the deletion stabilizes the αC helix of the kinase domain, which is located adjacent to the deletion site, by rigidifying the flexible β3-αC loop that accommodates the ELREA sequence. Consequently, the αC helix is stabilized in the "αC-in" active conformation that would prolong the time of the activated state. Moreover, in the mutant kinase, a salt bridge between E762 and K745, which is key for EGFR activity, was also stabilized during the simulation. Additionally, the interaction between EGFR and ATP was favored by ΔELREA EGFR over wild-type EGFR, as reflected by the number of hydrogen bonds formed and the free energy of binding. Simulation of inactive EGFR suggested the deletion would promote a shift from the inactive conformation towards active EGFR, which is supported by the inward movement of the αC helix. The MDS results also align with the effects of tyrosine kinase inhibitors on ΔELREA and wild-type EGFR lung cancer cell lines, where more pronounced inhibition was observed against ΔELREA than for wild-type EGFR by inhibitors recognizing the active kinase conformation.
Insights
A common deletion mutation in epidermal growth factor receptor (EGFR) stabilizes its active conformation, enhancing kinase activity and ATP binding. This finding explains increased sensitivity to targeted therapies in non-small cell lung cancer.
Area of Science:
- Molecular Biology
- Biochemistry
- Structural Biology
Background:
- Epidermal growth factor receptor (EGFR) is crucial for cell growth and survival.
- EGFR mutations, particularly deletions, are linked to non-small cell lung cancer (NSCLC) development.
- Understanding mutation-induced structural changes is key to targeted cancer therapy.
Purpose of the Study:
- To investigate the structural impact of the EGFR Δ746ELREA750 deletion mutation.
- To elucidate how this mutation increases EGFR kinase activity.
- To correlate structural findings with observed drug responses in NSCLC.
Main Methods:
- Molecular dynamics simulations were employed to model wild-type and mutant EGFR.
- Simulations analyzed the conformational stability and dynamics of the EGFR kinase domain.
- Binding interactions with ATP and effects of tyrosine kinase inhibitors were assessed.
Main Results:
- The Δ746ELREA750 deletion stabilizes the active 'αC-in' conformation of the EGFR kinase domain.
- The mutation enhances the stability of a key salt bridge (E762-K745) critical for kinase activity.
- Δ746ELREA750 EGFR exhibits stronger ATP binding and increased sensitivity to active-site inhibitors compared to wild-type.
Conclusions:
- The Δ746ELREA750 deletion promotes a shift towards the active EGFR conformation, prolonging its active state.
- Structural stabilization by the mutation underlies increased kinase activity and therapeutic vulnerability.
- Findings support the mechanism of enhanced efficacy of EGFR inhibitors in NSCLC patients with this mutation.
More Related Videos
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016